Results 11 to 20 of about 2,487,415 (296)

Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line [PDF]

BMC Cancer, 2006
Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping, Zhang Zhiyuan, Zhou Xiaojian, Qiu Weiliu, Chen Fangan, Chen Wantao   +5 more
doaj   +3 more sources

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]

PLoS ONE, 2014
Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet, Dongmin Dang, Stacy Achdjian, Yi Ye, Samuel G Katz, Brian L Schmidt   +5 more
doaj   +2 more sources

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation

Cancer Medicine, 2019
Objective Cisplatin is the first‐line chemotherapy for ovarian cancer. However, cisplatin resistance is severely affecting the treatment efficacy. FOXO3a has been reported to be involved in reversing chemotherapy resistance.
Lili Zhao, Shihai Liu, Donghai Liang, Tao Jiang, Xiaoyan Yan, Shengnan Zhao, Yuanwei Liu, Wei Zhao, Hongsheng Yu   +8 more
doaj   +2 more sources

p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer

Acta Biochimica et Biophysica Sinica, 2023
Cisplatin resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). p32 and OPA1 are the key regulators of mitochondrial morphology and function. This study aims to investigate the role
Yu Chun-Xia, Peng Zhe-Qing, Wang Tao, Qu Xin-Hui, Yang Ping, Huang Shao-Rong, Jiang Li-Ping, Tou Fang-Fang, Han Xiao-Jian   +8 more
doaj   +2 more sources

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway

Communications Biology
The development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established.
Yuwen Gong, Dongyang Gao, Yibo Shi, Guangrui Fan, Xiaoquan Yu, Enguang Yang, Hui Cheng, Junqiang Tian, Hui Ding, Shanhui Liu, Shengjun Fu, Yan Tao, Yuan Shui, Liang Cheng, Lanlan Li, Zhiping Wang   +15 more
doaj   +2 more sources

Understanding cisplatin resistance using cellular models [PDF]

, 2007
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, M, Davey, Mary W., Davey, Mary W, Stordal, B, Britta Stordal, Mary Davey, Stordal, Britta, Stordal, B., Davey, M.   +8 more
core   +5 more sources

Targeting the PHB2-ACSL3 Lipid-Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer. [PDF]

Adv Sci (Weinh)
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Xu L, Xiang W, Wang X, Pan Y, Gao J, Yang J, Wang Y, Zhu Z, Tong M, Jin L, Ye Y.   +10 more
europepmc   +2 more sources

Pulling a MAST1 on Cisplatin Resistance [PDF]

Cancer Cell, 2018
In this issue of Cancer Cell, Jin and colleagues use a kinome-wide screen to identify MAST1 as a cause of cisplatin resistance. They demonstrate that this kinase is a novel activator of MEK1 and the MAPK cascade and that it can harness pathway output to block cisplatin-induced cell death.
Ankita B, Jaykumar, Aroon S, Karra, Melanie H, Cobb   +2 more
openaire   +2 more sources

Molecular mechanisms of cisplatin resistance [PDF]

Oncogene, 2011
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.
L, Galluzzi, L, Senovilla, I, Vitale, J, Michels, I, Martins, O, Kepp, M, Castedo, G, Kroemer   +7 more
openaire   +2 more sources

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC

PeerJ, 2021
Backgrounds Cancer cell resistance to chemotherapy drugs such as Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin, and 5-fluorouracil account for the main reason of chemotherapy failure for HCC patients, especially for those with advanced HCC or metastasis patients.
Tang, Zuxiong, He, Jun, Zou, Jiayue, Yu, Shufei, Sun, Xiaoming, Qin, Lei   +5 more
openaire   +4 more sources